Equibles does not estimate personal net worth.
Get an email with a short summary when Arcutis Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ARQT alertsThe proxy statement of Arcutis Biotherapeutics, Inc. reports total compensation of $3,016,508 for Patrick Burnett in fiscal 2025, including a base salary of $535,000. Disclosed compensation is on record for 6 fiscal years. Patrick Burnett has spoken on 4 earnings calls across 1 company, most recently for Arcutis Biotherapeutics, Inc. on August 5, 2026. Arcutis Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arcutis Biotherapeutics, Inc. includes Todd Franklin Watanabe (CEO and Board Member), Latha Vairavan (CFO), Masaru Matsuda (General Counsel) and 7 others.
“As outside of today's call, Frank highlighted our focus across the grow, expand, and build pillars of our corporate strategy. I'd like to provide some additional context for the clinical components of each pillar.”
“In the first quarter, we continue to make significant progress in our efforts to support young children and infants suffering from plaque psoriasis and atopic dermatitis.”
“Ensuring that we can deliver Zarev to as broad a number of individuals with psoriasis, seborrheic dermatitis, and atopic dermatitis as possible, thereby benefiting from the unique profile of this drug, remains a top priority for us.”
“In the quarter, as you come to expect from us, we made significant progress against our clinical and regulatory objectives as we received FDA approval for Zarev foam 0.3% for scalp and body poxeriasis, initiated our Phase II trial for Zarev cream 0.05% in infants with atopic dermatitis, and submitted our IND…”
Proxy statement
Start not stated–present
Last confirmed April 21, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Arcutis Biotherapeutics, Inc. (ARQT) | M.D., Ph.D. Chief Medical Officer | $535,000 | $3,016,508 |
| 2024 | Arcutis Biotherapeutics, Inc. (ARQT) | M.D., Ph.D. Chief Medical Officer | $504,203 | $2,513,050 |
| 2023 | Arcutis Biotherapeutics, Inc. (ARQT) | M.D., Ph.D. Chief Medical Officer | $477,267 | $1,666,345 |
| 2022 | Arcutis Biotherapeutics, Inc. (ARQT) | M.D., Ph.D. Chief Medical Officer | $457,167 | $1,584,078 |
| 2021 | Arcutis Biotherapeutics, Inc. (ARQT) | M.D., Ph.D. Chief Medical Officer | $437,500 | $1,671,128 |
| 2020 | Arcutis Biotherapeutics, Inc. (ARQT) | M.D., Ph.D. Chief Medical Officer | $170,833 | $6,849,038 |
